Clinical Trial Update: Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures [Phase 3]

View source ↗

Summary

Phase 3 trial results posted assessing long-term lacosamide as monotherapy and as adjunctive therapy for partial-onset seizures in epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• lacosamide (Vimpat) (lacosamide)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2015-06-03